Larimar Therapeutics/LRMR

$6.64

4.08%
-
1D1W1MYTD1YMAX

About Larimar Therapeutics

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. It intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.

Ticker

LRMR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Carole Ben-Maimon

Employees

42

Headquarters

Bala cynwyd, United States

LRMR Metrics

BasicAdvanced
$449.79M
Market cap
-
P/E ratio
-$0.84
EPS
0.95
Beta
-
Dividend rate
$449.79M
0.9536
$13.68
$2.18
625.74K
9.486
-33.24%
-38.36%
-36.56%
3.788
5.504
45.64%

What the Analysts think about LRMR

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 5 analysts.
237.35% upside
High $27.00
Low $10.00
$6.64
Current price
$22.40
Average price target

LRMR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-12.9M
43.33%
Profit margin
0%
-

LRMR Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 21.26%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.15
-$0.19
-$0.21
-$0.30
-
Expected
-$0.25
-$0.20
-$0.22
-$0.25
-$0.24
Surprise
-39.02%
-2.56%
-6%
21.26%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Larimar Therapeutics stock?

Larimar Therapeutics (LRMR) has a market cap of $407.04M as of April 20, 2024.

What is the P/E ratio for Larimar Therapeutics stock?

The price to earnings (P/E) ratio for Larimar Therapeutics (LRMR) stock is 0 as of April 20, 2024.

Does Larimar Therapeutics stock pay dividends?

No, Larimar Therapeutics (LRMR) stock does not pay dividends to its shareholders as of April 20, 2024.

When is the next Larimar Therapeutics dividend payment date?

Larimar Therapeutics (LRMR) stock does not pay dividends to its shareholders.

What is the beta indicator for Larimar Therapeutics?

Larimar Therapeutics (LRMR) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Larimar Therapeutics stock price target?

The target price for Larimar Therapeutics (LRMR) stock is $22.4, which is 243.03% above the current price of $6.53. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Larimar Therapeutics stock

Buy or sell Larimar Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing